Leptospirosis

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Transmission and Risk Factors
  5. Clinical Presentation — Leptospiremic Phase
  6. Clinical Presentation — Immune Phase and Weil's Disease
  7. Diagnosis
  8. Treatment
  9. Complications
  10. Prevention
  11. References
  12. Connections
  13. Featured Videos

1. Overview

Leptospirosis is a systemic bacterial infection caused by pathogenic spirochetes of the species complex Leptospira interrogans. It is the most widespread zoonotic disease in the world, with an estimated burden exceeding one million severe cases and more than 60,000 deaths annually. The disease is most prevalent in tropical and subtropical regions, with the highest incidence in Southeast Asia, India, Brazil, and the Caribbean, where warm temperatures, flooding, and close contact between humans and reservoir animals create ideal transmission conditions.

Leptospirosis follows a characteristic biphasic course. The initial leptospiremic phase (days 1–7) features abrupt fever, severe headache, and intense myalgia — particularly in the calf muscles, which is considered pathognomonic when present. Most patients recover after this phase. In approximately 10% of cases, however, a second immune-mediated phase emerges after a brief apparent recovery, culminating in the severe syndrome known as Weil's disease, defined by the triad of jaundice, acute kidney injury, and hemorrhage.

Named variants include Canicola fever (caused by L. canicola acquired from dogs, characterized predominantly by aseptic meningitis) and Fort Bragg fever (a pretibial rash variant caused by L. autumnalis, first described in soldiers at Fort Bragg, North Carolina). Despite its global importance, leptospirosis remains a neglected tropical disease, chronically underdiagnosed and underreported.

Back to Table of Contents


2. Epidemiology

The global burden of leptospirosis is concentrated in low- and middle-income tropical countries. Countries reporting the highest incidence rates include India, Brazil, Sri Lanka, Thailand, the Philippines, Indonesia, and several Caribbean island nations. The WHO estimates that leptospirosis accounts for nearly 500,000 cases requiring hospitalization each year, though surveillance is poor and true incidence is substantially higher.

A defining epidemiological feature is the relationship between flooding and outbreak amplification. Heavy rains flush rodent urine from burrows into waterways and mud, dramatically expanding environmental contamination. Large outbreaks following floods have been documented repeatedly in the Philippines after typhoons, in the Brazilian state of São Paulo, and across flood-affected districts of India. Climate change, which is increasing flood frequency in many endemic regions, is projected to expand leptospirosis burden further.

Specific occupational groups carry substantially elevated risk, including rice paddy farmers, sugarcane workers, sewer and sanitation workers, abattoir workers, military personnel engaged in jungle training, veterinarians, agricultural workers, and competitive swimmers and triathletes who train in open freshwater. In the United States, leptospirosis is uncommon — roughly 100 to 200 cases are reported annually — with most cases concentrated in Hawaii and Puerto Rico, where tropical conditions persist. Cases in the continental United States frequently involve travel to endemic regions or recreational freshwater exposure.

Leptospirosis disproportionately affects impoverished urban populations in endemic countries, particularly slum communities where rodent density is high and sanitation infrastructure is poor. It qualifies formally as a neglected tropical disease under WHO criteria, receiving minimal research investment relative to its global mortality burden.

Back to Table of Contents


3. Pathophysiology

Leptospira interrogans are slender, obligately aerobic spirochetes measuring 0.1 µm in diameter and 6–20 µm in length with distinctive hooked ends at one or both poles. They are uniquely motile via internal periplasmic flagella (endoflagella) that wind through the periplasmic space rather than projecting externally as in other flagellated bacteria. This mechanism allows rapid corkscrew-like motility through viscous tissue matrices, facilitating tissue invasion.

The outer membrane of Leptospira contains lipopolysaccharide (LPS), but this leptospiral LPS is structurally distinct from classical gram-negative LPS and is significantly less pyrogenic than enterobacterial endotoxin. The organism's virulence is mediated by a complex of mechanisms including sphingomyelinase-like toxins, outer membrane proteins that bind host extracellular matrix components (fibronectin, collagen, laminin), and surface-exposed lipoproteins that activate toll-like receptors.

Following entry through skin abrasions, mucous membranes, or the conjunctiva, spirochetes enter the bloodstream and disseminate widely. Hepatic injury results from direct toxic effects of leptospiral membrane components on hepatocytes combined with inflammatory cytokine release; bile canalicular dysfunction produces conjugated hyperbilirubinemia. Renal injury primarily affects the proximal renal tubules — tubulointerstitial nephritis and tubular necrosis produce azotemia, hematuria, and leptospiruria; glomerular involvement is secondary. Pulmonary hemorrhage syndrome, a distinct and highly lethal complication, results from diffuse alveolar hemorrhage caused by endothelial damage and immune complex deposition — it is mechanistically different from cardiogenic pulmonary edema and does not respond to diuresis.

Systemic endothelial damage leads to capillary leak, thrombocytopenia, and hemorrhagic manifestations. The immune phase of illness, beginning around day 7–10, is triggered by antibody production against leptospiral antigens; circulating immune complexes deposit in the kidney, eye, and meninges, driving the complications that define Weil's disease. Persistent antigen in ocular tissues can provoke uveitis weeks to months after the acute illness has resolved.

Back to Table of Contents


4. Transmission and Risk Factors

Leptospirosis is transmitted from animal reservoir hosts to humans through direct or indirect contact with infected urine or urine-contaminated environments. Rats — particularly the black rat (Rattus rattus) and brown rat (Rattus norvegicus) — are the primary and most epidemiologically important reservoir worldwide. Infected reservoir animals typically do not develop disease; they shed leptospires continuously in urine for months to years. Other important reservoir hosts include cattle, dogs, pigs, horses, and a wide range of wildlife species.

Environmental persistence is a key factor: leptospires can survive for weeks to months in alkaline, moist soil and water. They are killed by acidic conditions, desiccation, and standard disinfectants. Flooding is the most dangerous environmental amplification event because it disperses contaminated material over wide areas and creates standing water where leptospires accumulate.

High-risk transmission scenarios include:

Leptospirosis is not transmitted person-to-person. Infected patients do not pose a risk to household contacts, caregivers, or healthcare workers under standard precautions.

Back to Table of Contents


5. Clinical Presentation — Leptospiremic Phase (Days 1–7)

The leptospiremic phase begins abruptly after an incubation period of 2 to 26 days (typically 5–14 days following exposure). The onset is sudden and dramatic, frequently leading patients to seek care within 24–48 hours of symptom development.

Cardinal features of the leptospiremic phase:

During this phase, leptospires are recoverable from blood and cerebrospinal fluid. Most patients who receive appropriate antibiotic treatment during the leptospiremic phase recover fully without progressing to the second phase. Without treatment, fever typically subsides after 3–7 days, followed by a brief apparent improvement before — in susceptible individuals — the immune phase begins.

Back to Table of Contents


6. Clinical Presentation — Immune Phase and Weil's Disease

After the initial leptospiremic phase, approximately 90% of patients recover fully. In the remaining 10%, an apparent improvement lasting 1 to 3 days is followed by return of fever and the onset of the immune (leptospiruria) phase, driven by antibody production and immune complex deposition rather than active bacteremia.

Weil's disease — the severe icteric form of leptospirosis — is defined by its classic triad:

  1. Jaundice — deeply yellow sclera and skin from conjugated hyperbilirubinemia; the liver injury is primarily hepatocellular with bile canalicular dysfunction, not cholestatic obstruction
  2. Acute kidney injury — tubular necrosis with rising creatinine, oliguria or anuria, hematuria, and proteinuria; dialysis is required in severe cases
  3. Hemorrhage — driven by thrombocytopenia and endothelial capillary leak, producing petechiae, ecchymoses, epistaxis, and most critically, pulmonary hemorrhage syndrome — diffuse alveolar hemorrhage that manifests as hemoptysis, rapidly progressive respiratory failure, and ARDS with high mortality (up to 50% in some series)

Additional immune-phase manifestations include:

Back to Table of Contents


7. Diagnosis

Diagnosis rests on a combination of clinical suspicion — particularly in patients with fever, calf myalgia, and conjunctival suffusion following relevant exposure — and laboratory confirmation. Early clinical diagnosis is critical because antibiotic efficacy is greatest when treatment begins within the first week.

Direct detection methods (useful early, first 7 days):

Serological methods:

Characteristic laboratory findings:

Back to Table of Contents


8. Treatment

Early antibiotic therapy reduces severity and duration of illness when initiated promptly. Treatment should not be delayed while awaiting confirmatory serology in patients with a compatible clinical presentation and relevant exposure history.

Mild to moderate disease (oral therapy):

Severe disease / Weil's disease (intravenous therapy):

Supportive care for severe complications:

A Jarisch-Herxheimer reaction — fever, rigors, and transient clinical worsening within 2 hours of the first antibiotic dose — can occur with leptospirosis treatment, as with other spirochetal infections. It is self-limiting and should not prompt discontinuation of antibiotics.

Back to Table of Contents


9. Complications

The majority of leptospirosis cases resolve fully with timely treatment. Serious complications arise predominantly in patients who develop Weil's disease or present late without antibiotic therapy.

Acute complications:

Late complications:

Back to Table of Contents


10. Prevention

Prevention requires a combination of personal protective measures, environmental control, and public health infrastructure. No universally available vaccine exists for humans, though vaccines have been deployed in some countries.

Personal protection:

Chemoprophylaxis:

Vaccines:

Environmental and public health measures:

Back to Table of Contents


11. References

  1. Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757–771. PMID 14652202
  2. Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296–326. PMID 11292640
  3. Victoriano AF, Smythe LD, Gloriani-Barzaga N, et al. Leptospirosis in the Asia Pacific region. BMC Infect Dis. 2009;9:147. PMID 19732423
  4. Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Curr Opin Infect Dis. 2011;24(5):484–489. PMID 21799414
  5. Lau CL, Smythe LD, Craig SB, Weinstein P. Climate change, flooding, urbanisation and leptospirosis: fuelling the fire? Ann N Y Acad Sci. 2010;1230:26–34. PMID 22150072
  6. Rajapakse S, Rodrigo C, Balaji K, Fernando SD. Treatment of leptospirosis: current evidence and gaps. J Antimicrob Chemother. 2011;66(4):733–742. PMID 21393206
  7. Daher EF, Abreu KL, da Silva Júnior GB. Leptospirosis-associated acute kidney injury. Am J Trop Med Hyg. 2010;82(2):201–207. PMID 20134004
  8. Marotto PC, Nascimento CM, Eluf-Neto J, et al. Acute lung injury in leptospirosis: clinical and laboratory features, outcome, and factors associated with mortality. Clin Infect Dis. 1999;28(2):268–273. PMID 10064238
  9. Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(1):e0003898. PMID 25629176
  10. Trivedi SV, Vasava AH, Bhatia LC, Patel TC, Patel NK, Patel NT. Cyclophosphamide in pulmonary alveolar haemorrhage due to leptospirosis. J Postgrad Med. 2010;56(3):179–184. PMID 20739759
  11. Panaphut T, Domrongkitchaiporn S, Vibhagool A, Thinkamrop B, Susaengrat W. Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis. Clin Infect Dis. 2003;36(12):1507–1513. PMID 12802748
  12. Haake DA, Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol. 2015;387:65–97. PMID 25388133

Back to Table of Contents


12. Connections

Back to Table of Contents